AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36301455 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi Jieyu Decoction (JJD)
Number of subjects: 140
Study 36301455 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 140
Study 34482187 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS + CR
Number of subjects: 73
Study 34482187 — intervention group
Group type: COMPARATOR
Intervention: IPS + Control
Number of subjects: 73
Study 32921262 — intervention group
Group type: EXPERIMENTAL
Intervention: Device arm (PFO closure) in low RoPE score group (<7)
Number of subjects: 2133
Study 32921262 — intervention group
Group type: COMPARATOR
Intervention: Medical arm in low RoPE score group (<7)
Number of subjects: 2133
Study 32921262 — intervention group
Group type: EXPERIMENTAL
Intervention: Device arm (PFO closure) in high RoPE score group (≥7)
Number of subjects: 2133
Study 32921262 — intervention group
Group type: COMPARATOR
Intervention: Medical arm in high RoPE score group (≥7)
Number of subjects: 2133
Study 32921262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of RoPE score
Number of subjects: 2133
Study 34607600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunomodulation with UTI-relevant Escherichia coli lysate (Uro-Vaxom) for 90 days
Number of subjects: 24
Study 34607600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33182482 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG)
Number of subjects: 423
Study 33182482 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes (GDM)
Number of subjects: 423
Study 33182482 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 423
Study 33182482 — intervention group
Group type: COMPARATOR
Intervention: Control (no GDM)
Number of subjects: 423
Study 33616910 — intervention group
Group type: EXPERIMENTAL
Intervention: Two proposed tools for inference about causal effects with invalid instruments (confidence intervals and novel test for null causal effect)
Number of subjects: 0
Study 33785557 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT plus lifestyle intervention (LSI)
Number of subjects: 61
Study 33785557 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT alone
Number of subjects: 61
Study 33785557 — intervention group
Group type: COMPARATOR
Intervention: Sham plus LSI
Number of subjects: 61
Study 33785557 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated FMTs
Number of subjects: 61
Study 33785557 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT with LSI
Number of subjects: 61
Study 33785557 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT plus LSI
Number of subjects: 61
Study 33902505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise intervention (AEI)
Number of subjects: 43
Study 33902505 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study 35718535 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Yiyi Baijiang Decoction combined with external application for four weeks
Number of subjects: 130
Study 35718535 — intervention group
Group type: COMPARATOR
Intervention: Acitretin Capsules and Calcipotriol Ointment
Number of subjects: 130
Study 32930784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex® Ag
Number of subjects: 119
Study 32930784 — intervention group
Group type: COMPARATOR
Intervention: Biobrane™
Number of subjects: 119
Study 33475736 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated umbilical cord blood (UCB) transplantation
Number of subjects: 368
Study 33475736 — intervention group
Group type: COMPARATOR
Intervention: HLA-haploidentical bone marrow transplantation
Number of subjects: 368
Study 32033922 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (13 μg)
Number of subjects: 20
Study 32033922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 36447332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (BMT)
Number of subjects: 0
Study 36447332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 0
Study 36447332 — intervention group
Group type: COMPARATOR
Intervention: Active comparison group (QoL)
Number of subjects: 0
Study 34703035 — intervention group
Group type: EXPERIMENTAL
Intervention: Flebitis Zero project intervention
Number of subjects: 656
Study 34703035 — intervention group
Group type: COMPARATOR
Intervention: Control Group (prior to intervention)
Number of subjects: 656
Study 34109545 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached clinics (received online toolkit plus weekly assistance from a distance coach for 12 months)
Number of subjects: 2484
Study 34109545 — intervention group
Group type: COMPARATOR
Intervention: Non-coached clinics (received online toolkit with evidence-based tools and QI coaching manual)
Number of subjects: 2484
Study 34109545 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached clinics
Number of subjects: 2484
Study 34109545 — intervention group
Group type: COMPARATOR
Intervention: Non-coached clinics
Number of subjects: 2484
Study 33020648 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab (400 mg every 4 weeks) + Dabrafenib (150 mg twice daily) + Trametinib (2 mg once daily)
Number of subjects: 36
Study 33020648 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab + Dabrafenib + Trametinib
Number of subjects: 36
Study 34350657 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wavelength bright light therapy (BLT)
Number of subjects: 63
Study 34350657 — intervention group
Group type: EXPERIMENTAL
Intervention: Long wavelength bright light therapy (BLT)
Number of subjects: 63
Study 34848798 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application-based provision of fertility-related information for one week
Number of subjects: 3765
Study 34848798 — intervention group
Group type: COMPARATOR
Intervention: General information about women’s healthcare (Control)
Number of subjects: 3765
Study 34848798 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application-based provision of fertility-related information
Number of subjects: 3765
Study 32375722 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image assessment using Fisher Body Image Questionnaire; Mean score: 163.26±20.38
Number of subjects: 307
Study 32375722 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety assessment using Spielberger Anxiety Questionnaire; Mean score: 12.00±7.71
Number of subjects: 307
Study 32375722 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression assessment using Beck Depression questionnaire; Mean score: 42.70±8.40
Number of subjects: 307
Study 32375722 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear correlation analysis; Body image as a predictor for depression and anxiety
Number of subjects: 307
Study 35030011 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily
Number of subjects: 532
Study 35030011 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily
Number of subjects: 532
Study 34242108 — intervention group
Group type: EXPERIMENTAL
Intervention: Roll Stability Control (RSC) fitment
Number of subjects: 0
Study 34242108 — intervention group
Group type: COMPARATOR
Intervention: Non-fitment of Roll Stability Control (RSC)
Number of subjects: 0
Study 32696895 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) with antidepressants
Number of subjects: 24
Study 32696895 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants only (Control)
Number of subjects: 24
Study 33952735 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of vegetable oil of Vitis vinifera L. or Persea americana L. (10 mL)
Number of subjects: 2
Study 32474978 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention support
Number of subjects: 10
Study 32474978 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessing additional support from family intervention
Number of subjects: 10
Study 32474978 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating openly with the individual
Number of subjects: 10
Study 32474978 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging with services for the individual
Number of subjects: 10
Study 34764637 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (a bolus of 0.1 mg kg‐1, iv)
Number of subjects: 0
Study 34764637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (a bolus of 0.5 mg kg‐1, iv)
Number of subjects: 0
Study 34764637 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (0.9% normal saline, iv)
Number of subjects: 0
Study 32584935 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of UDCA
Number of subjects: 521
Study 32584935 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of UDCA
Number of subjects: 521
Study 32584935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study 35817022 — intervention group
Group type: EXPERIMENTAL
Intervention: sotagliflozin 400 mg
Number of subjects: 40
Study 35817022 — intervention group
Group type: COMPARATOR
Intervention: empagliflozin 25 mg
Number of subjects: 40
Study 34878992 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring group (study 1)
Number of subjects: 297
Study 34878992 — intervention group
Group type: COMPARATOR
Intervention: Social norm information (study 1)
Number of subjects: 297
Study 34878992 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring group (study 2)
Number of subjects: 297
Study 34878992 — intervention group
Group type: COMPARATOR
Intervention: Social norm information (study 2)
Number of subjects: 297
Study 616117540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 598
Study 616117540 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 598
Study 616117540 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of retinal angiomatous proliferation (RAP) lesions
Number of subjects: 598
Study 616117540 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of subretinal fluid
Number of subjects: 598
Study 616117540 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of sub-RPE fluid
Number of subjects: 598
Study 616117540 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal sub-RPE fluid
Number of subjects: 598
Study 616117540 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafoveal fluid
Number of subjects: 598
Study 34350546 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-ER 32 mg
Number of subjects: 25
Study 34350546 — intervention group
Group type: COMPARATOR
Intervention: TAcs 40 mg
Number of subjects: 25
Study 36315249 — intervention group
Group type: EXPERIMENTAL
Intervention: Innominate artery cannulation
Number of subjects: 111
Study 36315249 — intervention group
Group type: COMPARATOR
Intervention: Axillary artery cannulation
Number of subjects: 111
Study 33957783 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture plus standard care (ASC)
Number of subjects: 120
Study 33957783 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture plus standard care (SSC)
Number of subjects: 120
Study 33957783 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 120
Study 32604218 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET) for 16 weeks, ≤ 60 min of moderate-intensity ET 3 times/week
Number of subjects: 116
Study 32604218 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET)
Number of subjects: 116
Study 32604218 — intervention group
Group type: COMPARATOR
Intervention: Attention control (CON)
Number of subjects: 116
Study 35034431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium injection at 1 times dose (Group A)
Number of subjects: 90
Study 35034431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium injection at 1.5 times dose (Group B)
Number of subjects: 90
Study 35034431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium injection at 2 times dose (Group C)
Number of subjects: 90
Study 33757719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cupping therapy
Number of subjects: 90
Study 33757719 — intervention group
Group type: COMPARATOR
Intervention: Sham cupping therapy
Number of subjects: 90
Study 32811738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 min stair climbing and descending bouts (SCD)
Number of subjects: 30
Study 32811738 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min stair climbing and descending bouts (SCD)
Number of subjects: 30
Study 32811738 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min stair climbing and descending bouts (SCD)
Number of subjects: 30
Study 32811738 — intervention group
Group type: COMPARATOR
Intervention: 0 min (seated control)
Number of subjects: 30
Study 34878637 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training plus high-intensity interval training (ExComb)
Number of subjects: 945
Study 34878637 — intervention group
Group type: EXPERIMENTAL
Intervention: ExComb (Men)
Number of subjects: 945
Study 34878637 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 1 metabolic equivalent of task increase in peak oxygen uptake
Number of subjects: 945
Study 34878637 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants whose peak oxygen uptake decreased
Number of subjects: 945
Study 34878637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 945
Study 33472211 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin challenge test (OCT) - infusion of oxytocin 5 IU/500 mL Ringer lactate at a rate of 12 mL/h, doubling every 10 min until inducing 5 uterine contractions per 15-min interval.
Number of subjects: 1450
Study 33472211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not specified in detail)
Number of subjects: 1450
Study 36275949 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlearning after class
Number of subjects: 0
Study 36275949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no microlearning after class)
Number of subjects: 0
Study 35006022 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness bibliotherapy (experimental group)
Number of subjects: 0
Study 35006022 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study 33400910 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimally treated CHD patients
Number of subjects: 13153
Study 33400910 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels
Number of subjects: 13153
Study 33400910 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and BMI
Number of subjects: 13153
Study 33400910 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex and low physical activity
Number of subjects: 13153
Study 34837528 — intervention group
Group type: EXPERIMENTAL
Intervention: Peloid therapy (5 days a week for 3 weeks at 45 °C for 30 min each day)
Number of subjects: 156
Study 34837528 — intervention group
Group type: EXPERIMENTAL
Intervention: Peloid therapy
Number of subjects: 156
Study 34837528 — intervention group
Group type: COMPARATOR
Intervention: Control (home exercise program and cold application)
Number of subjects: 156
Study 34837528 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (6 treatment days 2 times a week)
Number of subjects: 156
Study 32663119 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy in 5 once-weekly fractions of 6.0 Gy
Number of subjects: 915
Study 32663119 — intervention group
Group type: EXPERIMENTAL
Intervention: 28.5 Gy in 5 once-weekly fractions of 5.7 Gy
Number of subjects: 915
Study 32663119 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy in 25 fractions (5 weeks)
Number of subjects: 915
Study 34849744 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD patients with pathological Q waves
Number of subjects: 1477
Study 34849744 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD patients with QTc interval increase
Number of subjects: 1477
Study 34849744 — intervention group
Group type: COMPARATOR
Intervention: Control patients (700 patients)
Number of subjects: 1477
Study 32156142 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed cycling combined with passive joint activities of upper limbs
Number of subjects: 107
Study 32156142 — intervention group
Group type: COMPARATOR
Intervention: Routine intensive care (Control)
Number of subjects: 107
Study 35552068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-Reperfusion (IR) injury
Number of subjects: 15
Study 35552068 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no IR injury)
Number of subjects: 15
Study 35552068 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of change in sweat sodium concentration
Number of subjects: 15
Study 35552068 — intervention group
Group type: EXPERIMENTAL
Intervention: Local sweat rate during ischemia
Number of subjects: 15
Study 34052847 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive SMART (RA-SMART) design
Number of subjects: 0
Study 34052847 — intervention group
Group type: COMPARATOR
Intervention: SMART design
Number of subjects: 0
Study 32049675 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS
Number of subjects: 100
Study 32049675 — intervention group
Group type: COMPARATOR
Intervention: TSH
Number of subjects: 100
Study 32653055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% twice daily
Number of subjects: 157
Study 32653055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% once daily
Number of subjects: 157
Study 32653055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 0.5% once daily
Number of subjects: 157
Study 32653055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 0.15% once daily
Number of subjects: 157
Study 32653055 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control group)
Number of subjects: 157
Study 32653055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream (all doses)
Number of subjects: 157
Study 36107535 — intervention group
Group type: EXPERIMENTAL
Intervention: Liriope platyphylla extract (LP) 1000 mg per day for 4 weeks
Number of subjects: 22
Study 36107535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin) 1000 mg per day for 4 weeks
Number of subjects: 22
Study 34585252 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg intrathecal methotrexate
Number of subjects: 53
Study 34585252 — intervention group
Group type: COMPARATOR
Intervention: 10 mg intrathecal methotrexate
Number of subjects: 53
Study 34585252 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 53
Study 36518417 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes group
Number of subjects: 85
Study 36518417 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 34059720 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergic protein-rich formula diet (P-FD)
Number of subjects: 130
Study 34059720 — intervention group
Group type: COMPARATOR
Intervention: Fat-rich formula diet (F-FD)
Number of subjects: 130
Study 35802191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate air‐powder abrasion (test-group 1)
Number of subjects: 20
Study 35802191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate air‐powder abrasion supplemented by amino acid buffered hypochlorite solution (test-group 2)
Number of subjects: 20
Study 35802191 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20
Study 35802191 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between test-group 1 and test-group 2
Number of subjects: 20
Study 32928049 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy tube change (day 4)
Number of subjects: 16
Study 32928049 — intervention group
Group type: COMPARATOR
Intervention: Late tracheostomy tube change (day 7)
Number of subjects: 16
Study 32967877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²) followed by intravenous immunoglobulin (IVIg) with an initial dose of 2 g/kg and 1.5 g/kg injections once a month for 5 months (maximum dose: 100 g)
Number of subjects: 0
Study 32967877 — intervention group
Group type: COMPARATOR
Intervention: Rituximab alone (375 mg/m²)
Number of subjects: 0
Study 34044830 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol 2.5 μg/kg
Number of subjects: 480
Study 34044830 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol 5 μg/kg
Number of subjects: 480
Study 34044830 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 7.5 μg/kg
Number of subjects: 480
Study 34044830 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 10 μg/kg
Number of subjects: 480
Study 32247598 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided rectus sheath block (LG RSB)
Number of subjects: 48
Study 32247598 — intervention group
Group type: COMPARATOR
Intervention: Transincisional rectus sheath block (TI RSB)
Number of subjects: 48
Study 32247598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LG and TI RSB
Number of subjects: 48
Study 34260562 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlaser peeling mode (MM group) with depth of 60μm and a repetition rate of 20%
Number of subjects: 90
Study 34260562 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional ablative mode (FM group) with depth of 300μm and a fractional density of 8%
Number of subjects: 90
Study 34260562 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mode (CM group) with fractional depth of 200μm, density of 8%, and peeling depth of 30μm, repetition rate of 20%
Number of subjects: 90
Study 32319358 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MeD)
Number of subjects: 80
Study 32319358 — intervention group
Group type: COMPARATOR
Intervention: Control group (Iranian traditional diet)
Number of subjects: 80
Study 34070958 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-driven DDSS (differential diagnosis list)
Number of subjects: 22
Study 34070958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AI differential diagnosis list)
Number of subjects: 22
Study 34070958 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-driven DDSS
Number of subjects: 22
Study 32071329 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-faceted intervention (mailing reminders, health education, benchmarking PCP procedures)
Number of subjects: 2236